Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR.
Patterson AV, et al. Among authors: pullen sm.
Clin Cancer Res. 2007 Jul 1;13(13):3922-32. doi: 10.1158/1078-0432.CCR-07-0478.
Clin Cancer Res. 2007.
PMID: 17606726